Oncoscience GmbH develops therapeutic options for rare diseases in oncology.
Cancer is one of the leading causes of death worldwide and e.g. in Germany the second leading cause of death after cardiovascular diseases.
Once again, Nimotuzumab’s efficacy and safety in several cancer types were discussed and analyzed thorou...
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locall...
Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...